Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?

Seminars in Oncology
Howard A Burris

Abstract

Cancer patients are twice as likely to develop postoperative venous thromboembolism (VTE) than non-cancer patients undergoing the same surgical procedure. Causes of cancer-associated thrombosis include: the capacity of tumor cells and their products to interact with platelets, clotting, and fibrinolytic proteins. Aggressive antitumor therapy with agents such as platinum compounds, high-dose fluorouracil, mitomycin-C, tamoxifen, and growth factors increase the risk of cancer-associated thrombosis. Despite the high risk of VTE in patients with cancer, thromboprophylaxis in surgical and medical oncology patients is low. Initial therapy of VTE in patients with cancer is low-molecular-weight heparin (LMWH) or unfractionated heparin. Long-term secondary prophylaxis of VTE is generally accomplished with oral anticoagulants, primarily warfarin. Evidence supports the use of LMWH for prevention and treatment of cancer-associated thrombosis because it is more easily administered, does not require laboratory monitoring, has a lower risk of adverse events, and is more cost effective than unfractionated heparin. In addition, the antineoplastic effects of LMWH have been demonstrated, including direct antitumor, antiangiogenic, and immune syst...Continue Reading

References

Jun 1, 1983·The Journal of Clinical Investigation·M ColucciN Semeraro
Jan 1, 1995·Annual Review of Medicine·G J Broze
Jun 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·D A HoppensteadtE W Bermes
Mar 27, 1995·Archives of Internal Medicine·A W LensingJ Hirsh
Oct 1, 1996·Haemostasis·P M Sandset
Jun 13, 2001·Pharmacotherapy·E Racine
Sep 11, 2001·Acta Haematologica·F R Rickles, M N Levine
Nov 13, 2001·British Journal of Haematology·J WangH C Kwaan
Dec 26, 2001·Gynecologic Oncology·Mark A MorganJohn J Mikuta
Aug 13, 2002·Current Opinion in Hematology·Patricia M Fernandez, Frederick R Rickles
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Jun 20, 2003·Circulation·Agnes Y Y Lee, Mark N Levine
Jul 11, 2003·The New England Journal of Medicine·Rodger L Bick
Jul 11, 2003·The New England Journal of Medicine·Agnes Y Y LeeUNKNOWN Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Veno
Aug 5, 2003·The Oncologist·Ajay K KakkarJohn Wong
Sep 13, 2003·Chest·Frederick R RicklesPatricia M Fernandez
Oct 22, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Francisco RobertDelicia E Carey
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil GoldenbergSusan Solymoss
Jan 28, 2004·Archives of Internal Medicine·Hans-Martin M B OttenMartin H Prins
Feb 27, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Elenir B C AvritscherLinda S Elting
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ajay K KakkarRobin C N Williamson
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ErmanI Celik
Dec 1, 2004·The Journal of Laboratory and Clinical Medicine·Ellen BrodinJohn-Bjarne Hansen
Jan 4, 2005·American Journal of Nephrology·Jolanta MałyszkoMichał Myśliwiec
Jan 5, 2005·Seminars in Thrombosis and Hemostasis·Jawed FareedRodger L Bick
Jan 6, 2005·The Oncologist·Leo R ZacharskiManuel Monreal
Jan 11, 2005·Hematology/oncology Clinics of North America·Rodger L BickDeborah A Hoppensteadt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Jennifer Nishioka, Susan Goodin
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
J J NegusAlexander T Cohen
Expert Opinion on Pharmacotherapy
Agnes Y Y Lee
© 2022 Meta ULC. All rights reserved